Skip to main content Skip to search Skip to main navigation

PIC/S: Final guideline on Data Management and Integrity

After five years of drafting, PIC/S has now published the final version of a new guideline on data integrity, the PIC/S Guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). The document has already been applied in practice on a trial basis during this time and has been modified twice.

The resulting feedback was incorporated in the final version. Although the document is primarily addressed to inspectors, it is of course of interest to all pharmaceutical manufacturers. The document came into force on 1 July 2021.

With its remarkable 63 pages, the document covers all aspects that are to be taken into account in the handling of data in the GMP/GDP field. From basic principles, such as the ALCOA principle, to considerations for paper-based or computerised systems or the handling of so-called "findings" and potential risks, all areas are covered.Outsourcing activities and resulting actions such as audits, secure supply chain considerations or document verifications are discussed in a separate section. This also applies to necessary regulatory interventions: Possible "deficiencies" in data management are categorised and suggestions are made on how to address them. A comprehensive glossary concludes the document.


Source:
PIC/S: Q&A on Data Management and Integrity

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: New Guideline on Elemental Impurities in Veterinary Medicinal Products

EMA: New Guideline on Elemental Impurities in Veterinary Medicinal Products

The EMA has published the new Guideline on risk management requirements for elemental impurities in veterinary medicinal products (EMA/CVMP/426245/2023). It was developed to consolidate the existing documents on risk assessment and the management of elemental impurities in veterinary medicinal products into a single, clearly structured guideline.
Read more
Organic Impurities in Active Pharmaceutical Ingredients – Nitrosamines

Organic Impurities in Active Pharmaceutical Ingredients – Nitrosamines

Since the unexpected discovery of N-nitrosamines in sartans in 2018, what began as isolated recalls has evolved into a permanent, lifecycle-wide compliance challenge for the pharmaceutical industry. With tightening EMA and FDA expectations, substance-specific limits, and intensified GMP scrutiny, companies must now proactively control nitrosamine risks.

Read more
What are the Different Priorities of the Quality Assurance and IT Departments when Operating Computerised Systems?

What are the Different Priorities of the Quality Assurance and IT Departments when Operating Computerised Systems?

Here's the answer:
Read more
EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Previous
Next